Bioniz therapeutics
WebBioniz Therapeutics has raised a total of $14.3M in funding over 3 rounds. Their latest funding was raised on Aug 1, 2016 from a Series A round. Bioniz Therapeutics is funded by 4 investors. Takeda Ventures and Signatures Capital are the most recent investors. WebJul 31, 2024 · May 24, 2024 updated by: Bioniz Therapeutics. A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma. This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of …
Bioniz therapeutics
Did you know?
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. . Bioniz developed its novel structured-domain ... WebBioniz Therapeutics Inc Mar 2024 - Mar 2024 1 year 1 month. Irvine, CA Head of Global Development Almirall Jun 2024 - Nov 2024 2 years 6 …
WebJan 9, 2024 · Spanish drugmaker Almirall has signed an option agreement to acquire Bioniz Therapeutics, a clinical-stage biopharmaceutical company in California.. The move aligns with Almirall’s strategy to support its research and development pipeline and develop a treatment for onco-dermatology and immuno-dermatology.. If executed, the acquisition … WebMar 24, 2024 · Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases. Bioniz leverages its world class expertise in cytokine biology to develop a novel approach to selectively inhibit functionally redundant cytokines ...
WebFeb 16, 2024 · Equillium (NASDAQ:EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.; The consideration is comprised of an all-stock upfront ... WebMay 17, 2024 · Bioniz is building a pipeline of novel peptide therapeutics which selectively inhibit functionally redundant cytokines, while leaving the rest of the cytokine network unaffected. The company's lead product is BNZ-1, which targets cutaneous T-cell lymphoma and alopecia areata by simultaneously inhibiting cytokines IL-2, IL-9 and IL-15.
WebBioniz Therapeutics General Information. Description. Developer of multi-cytokine inhibitory therapeutics designed to address immuno-inflammatory diseases and cancer …
WebMar 24, 2024 · Bioniz Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class peptide-based multi-cytokine inhibitors for the treatment of cancer and autoimmune diseases. birmingham city fc liveWebJan 27, 2024 · Jan 27, 2024. Hannah Slater. Following phase 2 success, the FDA provided Bioniz Therapeutics with guidance for the design of a phase 3 trial of BNZ-1 in patients … dandridge tn 37725 countyWebBioniz is a biopharmaceutical company leading the discovery and development of multiple-cytokine inhibitory therapeutics to address immuno-inflammatory diseases and cancer, … dandridge tn city governmentWebFeb 16, 2024 · Equillium to host a conference call and webcast today at 8:00 a.m. Eastern Time. Equillium, Inc. EQ, a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe ... birmingham city fc logo pngWebEquillium, with only one asset in its pipeline thanks to an in-licensing deal, is expanding its drug development efforts via the acquisition of Bioniz Therapeutics. Equillium will pay up to $329 ... birmingham city fc latest newsWebBioniz Therapeutics has raised a total of $14.3M in funding over 3 rounds. Their latest funding was raised on Aug 1, 2016 from a Series A round. Bioniz Therapeutics is … dandridge tn court recordsWebMar 7, 2024 · Bioniz Therapeutics / Almirall has leveraged its proprietary multi-cytokine inhibitor platform technology to develop BNZ-1 for an immuno-dermatology franchise in vitiligo, cutaneous T-cell lymphoma and alopecia areata. Multi-cytokine inhibitor is selectively targeting three interleukins, IL-2, IL-9, and IL-15. ... birmingham city fc marketing assistant